Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XB002 |
| Synonyms | |
| Therapy Description |
XB002 is an antibody-drug conjugate (ADC) comprising a tissue factor (TF)-targeted monoclonal antibody linked to zovodotin, which potentially inhibits tumor growth (PMID: 39494690). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XB002 | XB-002|XB 002|Samatatug zovodotin | XB002 is an antibody-drug conjugate (ADC) comprising a tissue factor (TF)-targeted monoclonal antibody linked to zovodotin, which potentially inhibits tumor growth (PMID: 39494690). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Completed | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |